Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Sb8.5
Saccharomyces Boulardii – Forschung
Hilft wahrscheinlich
51 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Saccharomyces Boulardii scheint in 12 von 14 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2005–2026 mit einer typischen Studiengröße von 151 Teilnehmenden.
Basierend auf 51 Studien · 13 Meta-Analysen · 27 RCTs · 53,279 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
12geholfen2nicht geholfen· 37 weitere ohne bewertete Effektdaten
Nach Outcome
Digestive health & diarrheaProbiotische Hefe beugt Durchfall vor und behandelt ihn, stellt die Darmflora wieder her · 1-2 Wochen
Hilft wahrscheinlich48 Studien
Safety profile
Hilft vermutlich13 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung3 Studien
InflammationVorbeugung und Behandlung von Durchfall, Schutz des Darms · Tage bis 1 Woche
Zu wenige bewertete Studien2 Studien
In Zahlen
Aus 31 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
80%
über Studien hinweg
Untersuchte Personen
53k
typische Studie: 151 Personen
Stärkste Designs
40
13 gepoolt, 27 randomisiert
Zeigte Nutzen
86%
12/14 Studien
Wie lange Studien liefen
1–4 Wochen
3
1–3 Monate
2
3+ Monate
1
Untersuchte Populationen
Patients with H. pylori infection4
Patients with Helicobacter pylori infection3
Travelers3
Patients with gut pathogenic bacteria1
Aktives Forschungsgebiet
35 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
200520152026
1H. pylori eradication rateMeta-AnalyseCited 9×n=5,036 · very large study2025
S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.
Li M et al. · Frontiers in cellular and infection microbiology (2025)
S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.
2Pathogenic bacteria decolonizationMeta-AnalyseCited 40×n=2,871 · very large study2024
Protocol registration: PROSPERO (ID = CRD42021276045).
Rahman MN et al. · Gut microbes (2024)
Groß Nutzen
← SchlechterKein EffektBesser →
Likely real
This review aims to analyze available evidence from human-controlled trials to determine the effect size of probiotic interventions in decolonizing AMR pathogenic bacteria from the gut.
The persistence of pathogenic bacteria after treatment was 22%(probiotics) and 30.8%(placebo).
The pooled odds ratio was 0.59(95% CI:0.43-0.81), favoring probiotics with moderate certainty (p = 0.0001) and low heterogeneity (I2 = 49.2%, p = 0.0001).
3Acute infectious diarrhoea durationMeta-AnalyseCited 110×n=12,127 · very large study2020
Probiotics probably make little or no difference to the number of people who have diarrhoea lasting 48 hours or longer, and we are uncertain whether probiotics reduce the duration of diarrhoea.
Collinson S et al. · The Cochrane database of systematic reviews (2020)
Effect size was similar in the sensitivity analysis and marked heterogeneity persisted.
Effect size was similar and marked heterogeneity persisted in pre-specified subgroup analyses of the primary outcomes that included all studies.
In six trials (433 participants) of Lactobacillus reuteri, there was consistency amongst findings (I² = 0%), but risk of bias was present in all included studies.
4H. pylori eradication ratesMeta-AnalyseCited 56×n=3,592 · very large study2019
Our meta-analysis shows that S boulardii supplementation on standard eradication therapy significantly increased H pylori eradication rates and reduced the incidence of total side effects and some gastrointestinal adverse effects during eradication therapy.
Zhou BG et al. · Helicobacter (2019)
In addition, the need for discontinuation rate in S boulardii supplementation group was significantly lower than in the control group (RR = 0.33, 95%CI:0.16-0.69, P = .003; moderate quality evidence).
Our meta-analysis shows that S boulardii supplementation on standard eradication therapy significantly increased H pylori eradication rates and reduced the incidence of total side effects and some gastrointestinal adverse effects during eradication therapy.
The addition of S. boulardii to bismuth quadruple therapy significantly increased H. pylori eradication rates and decreased the adverse effects.
Jiang YZ et al. · BMC gastroenterology (2025)
Kaum spürbar Schaden
← SchlechterKein EffektBesser →
Notably, S. boulardii supplementation to bismuth quadruple therapy significantly improved H. pylori eradication rates (RR = 1.08, 95% CI: 1.04-1.12) and reduced the incidence of total adverse effects (RR = 0.53, 95% CI: 0.45-0.62).
We recommend adding 500 mg/day S. boulardii concurrently with bismuth quadruple therapy and continuing this therapy for > 10 days for optimal H. pylori eradication efficacy.
Adding probiotics, particularly S. boulardii or multi-strain combinations, to BQT significantly improves eradication efficacy and decreases treatment-related adverse events.
Liu YH et al. · International journal of antimicrobial agents (2025)
Groß Schaden
← SchlechterKein EffektBesser →
Likely real
PBQT significantly improved H. pylori eradication rates compared to BQT alone (pooled odds ratio [OR] = 1.49, 95% confidence interval [CI] 1.20-1.85; P = 0.0004), with low heterogeneity (I² = 0%).
Subgroup analyses demonstrated that both Saccharomyces boulardii (OR = 1.62; P < 0.05) and multi-strain probiotics (OR = 1.66; P < 0.05) significantly enhanced eradication rates.
Concomitant administration of probiotics with antibiotics also yielded significant benefits (OR = 1.48, 95% CI 1.14-1.92; P = 0.003).
12Probiotic efficacy across conditionsSystematische ÜbersichtCited 162×2018
The choice of an appropriate probiotic is multi-factored, based on the mode and type of disease indication and the specific efficacy of probiotic strain(s), as well as product quality and formulation.
Sniffen JC et al. · PloS one (2018)
Of the 22 types of probiotics reviewed, 15 (68%) had strong-moderate evidence for efficacy for at least one type of disease.
The choice of an appropriate probiotic is multi-factored, based on the mode and type of disease indication and the specific efficacy of probiotic strain(s), as well as product quality and formulation.
14Mucositis incidence and symptom improvementSystematische ÜbersichtCited 33×n=15 · very small study2019
Our analysis suggests that a combination of Bifidobacterium longum, Lactobacillus acidophilus, Bifidobacterium breve, Bifidobacterium infantis, and Saccharomyces boulardii could be a good combination of probiotics to reduce incident rates of mucositis or ameliorate its symptoms in chemo or radiotherapy treated patients.
Picó-Monllor JA et al. · Nutrients (2019)
After applying our inclusion and exclusion criteria, 15 studies were accepted for review and critical analysis.
15Prevention of antibiotic-associated diarrheaMeta-AnalyseCited 334×n=31 · small study2010
The use of S. boulardii as a therapeutic probiotic is evidence-based for both efficacy and safety for several types of diarrhea.
McFarland LV · World journal of gastroenterology (2010)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
Of 31 randomized, placebo-controlled treatment arms in 27 trials (encompassing 5029 study patients), S. boulardii was found to be significantly efficacious and safe in 84% of those treatment arms.
A meta-analysis found a significant therapeutic efficacy for S. boulardii in the prevention of antibiotic-associated diarrhea (AAD) (RR = 0.47, 95% CI: 0.35-0.63, P < 0.001).
In adults, S. boulardii can be strongly recommended for the prevention of AAD and the traveler's diarrhea.
17Prevention of Clostridium difficile infection relapseSystematische ÜbersichtCited 51×2009
S boulardii seems to be well tolerated and may be effective for secondary prevention in some specific patient populations with particular concurrent antibiotic treatment.
Tung JM et al. · Canadian journal of gastroenterology = Journal canadien de gastroenterologie (2009)
Groß Nutzen
← SchlechterKein EffektBesser →
Borderline
One trial showed a reduction of relapses in patients experiencing recurrent CDI (RR=0.53; P<0.05).
The other demonstrated a trend toward reduction of CDI relapse in the recurrent treatment group of patients receiving high-dose vancomycin (RR=0.33; P=0.05).
These studies lacked the power to detect statistically significant differences.
19Helicobacter pylori eradication and adverse effectsRCTCited 19×n=156 · medium study2022
S. boulardii could significantly reduce some AEs of H. pylori eradication therapy, but effectiveness of Lactobacillus reuteri on these cases was not significant.
Naghibzadeh N et al. · BMC gastroenterology (2022)
S. boulardii could significantly reduce some AEs of H. pylori eradication therapy, but effectiveness of Lactobacillus reuteri on these cases was not significant.
It is recommended to conduct the future research with larger sample size in order to investigate the effect.
20Helicobacter pylori eradication ratesRCTCited 2×n=126 · medium study2024
Addition of S. boulardii to VA-dual for 10 days is as effective as the 14-days bismuth-based quadruple regimen while ensuring fewer adverse events and lesser cost.
Yu J et al. · BMC gastroenterology (2024)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Could be chance
The H. pylori eradication rates of VAS and ECAB groups by intention-to-treat analysis were 87.3% and 88.9% (P = 1.000) and by per-protocol analysis were 87.3% and 91.8% (P = 0.560), respectively.
Addition of S. boulardii to VA-dual for 10 days is as effective as the 14-days bismuth-based quadruple regimen while ensuring fewer adverse events and lesser cost.
This regimen is particularly suitable for low-BSA patients or non-smokers.